Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
80%(8 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
4
33%
Ph phase_2
6
50%
Ph phase_3
2
17%

Phase Distribution

4

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (33.3%)
Phase 26 (50.0%)
Phase 32 (16.7%)

Trials by Status

completed1083%
terminated18%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

NCT00410761
completedphase_2

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

NCT00098345
completedphase_2

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

NCT00358956
completedphase_2

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

NCT00659438
completedphase_2

Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine

NCT00753714
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00410761Phase 3

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Completed
NCT00098345Phase 2

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Completed
NCT00358956Phase 2

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Completed
NCT00659438Phase 2

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

Completed
NCT00753714Phase 2

Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine

Completed
NCT00753675Phase 2

Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

Completed
NCT00404924Phase 3

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Completed
NCT00807170Phase 1

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Terminated
NCT00450138Phase 1

Open Label, Phase I ZD6474 Head and Neck Cancer Study

Completed
NCT00499850Phase 1

Phase I FOLFOX Combination

Completed
NCT00995007Phase 2

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Completed
NCT01004419Phase 1

Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12